Features of metabolic correction in patients after percutaneous coronary intervention for acute coronary syndrome without ST elevation

Authors

  • L.S. Kholopov Odessa National Medical University,
  • N. V. Chumachenko Odessa National Medical University,
  • I. A. Sydorenko Odessa National Medical University,

DOI:

https://doi.org/10.14739/2310-1210.2016.2.69164

Keywords:

Metabolic Diseases, Quercetin, Percutaneous Coronary Intervention, Myocardial Ischemia

Abstract

Aim. Coronary artery disease (CAD) with concomitant metabolic syndrome (MS) leads to early disability and poor prognosis after urgent percutaneous coronary intervention (PCI) for acute coronary syndrome without elevation ST (ACS noST).

Mathods and results. With the aim of treatment effectiveness improvement, 64 patients were treated (M : F = 55 : 9, mean age 66.9±12.4 years) in two regimens – standard (group I) and with metabolic supplement (group II). Patients in groups didn`t differ in the major clinical, anamnestic, laboratory and instrumental parameters. It was found, that in the II group (n= 33), those patients received in addition to the standard therapy quercetin, 40 mg three times daily for 12.07±1.51 months, compared with the group I (n=31), number of patients with MS` criteria decreased to 48.5% (n=16) and 77.4% (n=24), respectively. These results were obtained by reducing the waist circumflex of patients in the group II compared to the group I (p=0.034) and body mass index (p=0.048); improvement of insulin resistance (calculated by index HOMA) in group II patients in comparison to the group I (p=0.049), fasting blood glucose (p=0.024), low density lipoproteins (p=0.049) and plasma thrombin (p=0.0002). High density lipoproteins were significantly higher in group II patients compared to the group I (p=0.049).

Conclusions: Long-term quercetin use in addition to standard therapy in patients with CAD and MS after PCI on the ACS without ST leads to the improvement of the system of metabolism due to the correction of the parameters of the metabolic syndrome. 

References

Maksyutina, N. P., Mojbenko, A. A., Mokhort, N. A., et al. (2012) Bioflavonoidy kak organoprotektory: kvercetin, korvitin, kvertin [Bioflavonoids as organoprotektors: quercetin, korvitin, quertin]. A.A. Mojbenko (Ed.). Kyiv: Naukova dumka. [in Ukrainian].

Hlushko, L. V., Nasrallakh, A. Kh., Fedorov, S. V. (2013) [Effect of quercetin on anti-inflammatory activity of peripheral blood monocytes in women with metabolic syndrome in postmenopausal]. News of pharmacy, 4(76), 79–81. [in Ukrainian].

Karpov, Yu. A., & Buza, V. V. (2011) Kak vesti bol'nogo posle chreskozhnogo koronarnogo vmeshatel'stva? [How keep the patient after percutaneous coronary intervention?]. Rossijskij medicinskij zhurnal, 19(26), 1604–1609. [in Russian].

Kuz'menko, M. O. (2013) Systemni ta molekuliarno-henetychni mekhanizmy remodeliuvannia sertsia ta yoho eksperymentalna terapiia za dopomohoiu bioflavonoidiv (Avtoref. dis…kand. biol. nauk). [System and molecular genetic mechanisms of cardiac remodeling and its experimental therapy with bioflavonoids]. (Extended abstract of candidate’s thesis). Kyiv. [in Ukrainian].

Chumakova, G. A., Veselovskaya, N. G., & Kozarenko, A. A. (2010) Faktory riska restenozov posle revaskulyarizacii miokarda u pacientov s metabolicheskim sindromom i sakharnym diabetom 2 tipa [Factors of risk of restenosis after myocardial revascularization in patients with metabolic syndrome and type 2 diabetes]. Serdce : zhurnal dlya praktikuyushikh vrachej, 9(1), 14–27. [in Russian].

Shimanovskij, N. L., Matyushin, A. I., & Rogovskij, V. S. (2013) Perspektivy primeneniya preparatov kvercetina dlya profilaktiki i lecheniya ateroskleroza [Prospects of application quercetin drug for prevention and treatment of atherosclerosis]. Medical Nature, 2(14), 66–69. [in USA].

Kuzmenko, M. A., Pavlyuchenko, V. B., Tumanovskaya, L. V., Dosenko, V. E., & Mojbenko, A. A. (2013) E′ksperimental'naya terapiya remodelirovaniya serdca s pomosch'yu preparatov kvercetina [Experimental therapy of cardiac remodeling with quercetin-containing drugs]. Patologicheskaya fiziologiya i e′ksperimental'naya terapiya, 2,17–22. [in Russian].

Galleano, M., Calabro, V., Prince, P., Litterio, M., Piotrkowski, B., Vazquez-Prieto, M., et al. (2012) Flavonoids and metabolic syndrome. Annals of the New York Academy of Sciences., 1259(1), 87–94. doi: 10.1111/j.1749-6632.2012.06511.x.

Kim, J., Mun, H., Lee, B., Yoon, S., Choi, E., Min, P., et al. (2010) Impact of Metabolic Syndrome and Its Individual Components on the Presence and Severity of Angiographic Coronary Artery Disease. Yonsei Medical Journal., 51(5), 676–682. doi: 10.3349/ymj.2010.51.5.676.

Mosawy, S. (2015) Effect of the flavonol quercetin on human platelet function: a review. Food and Public Health., 5(1), 1–9. doi: 10.5923/j.fph.20150501.01.

Downloads

How to Cite

1.
Kholopov L, Chumachenko NV, Sydorenko IA. Features of metabolic correction in patients after percutaneous coronary intervention for acute coronary syndrome without ST elevation. Zaporozhye Medical Journal [Internet]. 2016May23 [cited 2024Dec.25];18(2). Available from: http://zmj.zsmu.edu.ua/article/view/69164

Issue

No. 2 (2016): Zaporozhye medical journal

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)